

Correlation between double-stranded DNA and rheumatoid arthritis

MINGWEI LV^{1,2}, YIRUI WANG³, JUAN DU⁴, JINGYUE WANG⁴, ZHUO LI³, YANG HAN³, XINYU FENG⁵, XIAOFEN GUO⁵, HAORAN SHEN¹, YUGE WANG¹, GUANGLEI SHI⁵, YUHANG LIU⁵, WEIWEI CHEN³, QI ZHEN³, RUIMIN WANG⁴, LIANGDAN SUN^{6,7,8}

¹School of Basic Medicine, North China University of Science and Technology, Tangshan, Hebei, 063210, China

²Hebei Key Laboratory for Chronic Diseases, School of Basic Medicine, North China University of Science and Technology, Tangshan, Hebei, 063210, China

³North China University of Science and Technology Affiliated Hospital, Tangshan, 063000, China

⁴School of Public Health, North China University of Science and Technology, Tangshan, Hebei, 063210, China

⁵School of Clinical Medicine, North China University of Science and Technology, Tangshan, Hebei, 063210, China

⁶North China University of Science and Technology, Tangshan, Hebei, 063210, China

⁷Hebei Key Laboratory of Medical Engineering and Integrated Utilization of Saline-Alkali Land, Tangshan, Hebei, 063210, China

⁸Department of Dermatology, the First Affiliated Hospital of Anhui Medical University, Hefei, 230032, China

Abstract

Introduction: Rheumatoid arthritis (RA) is a chronic autoimmune disease influenced by environmental factors. Double-stranded DNA (dsDNA) serves as an antigen in various autoimmune diseases and is affected by meteorological factors. However, the relationships among the circulating dsDNA level, RA inflammatory immune mechanisms, and seasonal meteorological factors remain unclear.

Material and methods: Serum dsDNA levels were measured in patients with RA and healthy controls, and correlations with archived data on seasonal meteorological changes were examined. Quantitative PCR was performed to assess the gene expression of relevant receptor markers in the peripheral circulation of patients and controls.

Results: The mean serum dsDNA level was significantly higher in patients with RA than in controls (1.16 ± 0.36 ng/ml vs. 0.92 ± 0.20 ng/ml, $p < 0.001$). The expression of genes related to dsDNA receptors, single-stranded RNA receptors, dsRNA receptors, ALR inflammasome-associated inflammatory factors, interferon (IFN) $\alpha 1$, IFN $\beta 1$, and low-density lipoprotein was upregulated in patients with RA.

Conclusions: dsDNA levels in the peripheral circulation of patients with RA are elevated and affected by seasonal climatic factors. This elevation enhances the expression of ALR inflammasome-related inflammatory factors and type I IFN. These findings provide a foundation for future investigations into the mechanisms underlying the link between climate variability and RA progression.

Key words: rheumatoid arthritis, double-stranded DNA, temperature, season, AIM2.

(Cent Eur J Immunol 2026; 51 (1): 70-83)

Introduction

Rheumatoid arthritis (RA) is a long-lasting condition affecting the entire body that is driven by immune system dysfunction. It is characterized by the elevation of inflammatory factors in the blood, the excessive growth of synovial tissue, and the deterioration of bone and cartilage. These pathological changes arise from combinations of inherited traits and environmental triggers [1, 2]. RA affects 0.1-2.0% of the global population [3]. Although it can manifest at any age, it appears most commonly in individuals in their 30s to 50s, with women being disproportionately more affected than men [4].

Evidence from numerous studies highlights the pivotal impacts of environmental elements on the initiation and progression of various autoimmune conditions [5-9]. The mechanisms by which climatic factors influence the immune system remain unclear. Specific weather conditions, including colder climates, high barometric pressures, and increased moisture levels, may contribute to the triggering of RA [10-13]. However, scientific evidence regarding initial triggering factors remains limited, and conclusions about biomarkers are inconsistent [14-17]. These discrepancies may be attributed to differences in the climatic conditions of the geographic regions in which studies have been performed and in the research methodologies employed.

Correspondence: Prof. Liangdan Sun, North China University of Science and Technology, Tangshan, Hebei, 063210, China,

e-mail: ahmusld@163.com

Submitted: 24.11.2024, Accepted: 08.04.2025

Synergistic effects of meteorological factors and surface ultraviolet (UV) radiation can influence double-stranded DNA (dsDNA) [17-19]. As a type of extracellular circulating DNA, dsDNA has been recognized as an antigen that triggers immune responses in various autoimmune diseases, including systemic lupus erythematosus [20], systemic sclerosis [21], and primary Sjögren's syndrome [22]. Hajizadeh *et al.* [23] emphasized the relationship between dsDNA and rheumatoid factor in patients with RA. Contemporary studies and therapeutic strategies for RA focus largely on the discovery of diverse serum biomarkers, including rheumatoid factor and anti-citrullinated, anti-carbamylated, and anti-acetylated protein antibodies [24]. Multiple studies have identified DNA-sensing autoimmune inflammatory pathways, but our understanding of the relationship between circulating dsDNA levels and the pathogenesis of RA, and of the role of seasonal meteorological parameters, remains limited. To address this research gap, we investigated differences in the peripheral circulating serum dsDNA level between patients with RA and healthy controls, and potential associations of this level with seasonal temperatures and UV radiation levels. The elucidation of patterns of seasonal variation in the dsDNA level in RA may provide insights into the disease's pathogenesis and offer new directions for further research on the potential etiological role of dsDNA in RA.

Material and methods

Setting and participants

Our research group collected the case data in a tertiary hospital that provides care to more than 100,000 residents of a southern city in central and eastern China from September 2017 to October 2019. The participant dataset collected were the date of blood collection; patient sex, age, place of residence, past history, and family history; and RA clinical manifestations and treatment plans. All patients in the RA group fulfilled the 2010 European League Against Rheumatism/American College of Rheumatology criteria for RA and were diagnosed with the condition by rheumatologists. Subjects with concurrent autoimmune diseases and those who had previously received systemic immunosuppressive therapy were excluded. To mitigate potential bias, we employed propensity score matching (PSM) to healthy controls at a 1 : 3 ratio and caliper value of 0.2 using the MatchIt package in R (version 4.2.2; <https://www.r-project.org/>). We excluded cases with missing basic information (including those for which meteorological data were missing after PSM), and limited the sample to people living in the region to reduce errors such as time deviations due to differences in geographical and meteorological conditions and long-distance travel before treatment. The final sample comprised 152 participants with RA and 2944 healthy subjects who provided informed con-

sent to study participation. Baseline data on the patients enrolled in the study are provided in Table 1. The hospital's ethics committee approved the study.

Sample collection and handling

Qualified physicians collected two tubes of peripheral blood (3-6 ml each) from each participant. The samples were stored separately in sterile anticoagulant and procoagulant tubes. Fresh blood (0.5 ml) was drawn from the anticoagulant tube using a sterile nuclease-free pipette tip, aliquoted into several nuclease-free cryovials, labeled, and preserved in liquid nitrogen. The fresh blood in the procoagulant tube was centrifuged at 4°C and 4000 rpm for 30 minutes, and the supernatant was collected, aliquoted into cryovials, and stored at -80°C for long-term preservation.

Serum dsDNA detection

We used a quantitative method based on combined fluorescence detection to obtain serum dsDNA values. Using a commercial kit (cat. no. K900-2000-1; BioVision, USA), we prepared a 5 ng/ml dsDNA standard solution and diluted the 2X dsDNA dye with TE buffer and ultrapure water (18 MΩ·cm specific resistance). Then, 50, 48, 46, 44, 42, and 40 μl 1X TE buffer was added to a dark 96-well plate (Costar, Kennebunk, ME, USA) and 0, 2, 4, 6, 8, and 10 μl dsDNA standard solution was added to the buffer solution to obtain a reference standard curve. A 10-μl aliquot of each serum sample was added to 40 μl of buffer in a 96-well plate, and each sample was tested in triplicate (as technical replicates) to ensure accuracy. dsDNA dye (50 μl) was added to each well. The plate was then immediately covered and shaken in a box in the dark for 10 minutes. Finally, a cell imaging multi-mode reader (Cytation 5; BioTek, USA) was used to obtain a fluorescence value for each sample at 28°C and excitation and emission wavelengths of 480 and 530 nm, respectively. The initial concentration of dsDNA in each sample was calculated using this value and the standard curve.

Analysis of associations between dsDNA concentrations and concurrently recorded weather patterns

For a subsample of 152 patients with RA, weather data corresponding to the dates of disease onset (month and local monthly average temperature) and blood collection (UV index) were obtained through the online platform of China's National Meteorological Information Center (<http://data.cma.cn>). Patients who first visited the hospital in November-April (monthly average temperatures of 1.2-16.4°C) were allocated to the low-temperature group, and those who first visited the hospital in May-October (monthly average temperatures of 17-32.3°C) were allo-

Table 1. Baseline data of enrolled patients

ID	Sex	Age	Clinical manifestations
RA15	Male	51	Polyarticular swelling and pain for 3 years, worsened for 1 year with melena for 2 weeks
RA17	Male	66	Polyarticular swelling and pain for 6 months
RA20	Female	73	Joint swelling and pain for 18 years
RA27	Female	54	Polyarticular swelling and pain for 9 years
RA36	Female	57	Recurrent polyarticular swelling and pain for over 6 years, accompanied by hand tremors for 1 day
RA37	Female	66	Polyarticular swelling and pain for 10 years, bilateral lower limb swelling for 10 days
RA40	Female	75	Recurrent joint pain for over 20 years
RA45	Male	38	Recurrent polyarticular swelling and pain for over 1 year, worsened for 20 days
RA49	Female	47	Limited movement in proximal interphalangeal joints, swelling, tenderness, and patellar floating test positive in right wrist and bilateral knee joints
RA60	Male	33	Bilateral wrist joint pain for over 10 years, worsened for 6 months
RA74	Female	57	Recurrent polyarticular pain for over 10 years, worsened for 2 months
RA16	Female	56	Bilateral wrist and ankle joint swelling and pain
RA24	Female	76	Pain in bilateral knee, wrist, elbow, and shoulder joints
RA26	Female	58	Polyarticular swelling and pain for 6 months
RA64	Female	63	Diagnosed with rheumatoid arthritis for 11 years, planned for the 6th biological agent treatment
RA66	Female	49	Polyarticular swelling and pain for over 17 years, worsened for 3 days
RA67	Female	47	Recurrent systemic joint swelling and pain for 18 years, worsened for 1 month
RA73	Female	61	Polyarticular pain for 18 years, worsened with fever for 1 week
RA79	Female	59	Polyarticular swelling and pain for 26 years
RA84	Female	66	Polyarticular swelling and pain for 9 years
RA90	Female	52	Polyarticular pain for 3 years, dry mouth for 3 months
RA92	Female	50	Headache and fatigue for 17 years, polyarticular swelling and pain for over 10 months
RA93	Female	54	Polyarticular pain for over 4 years, fever for 4 days
RA94	Female	54	Limb joint pain for 20 days
RA98	Female	69	Limb joint swelling and pain for 10 years, worsened for 1 year
RA99	Male	68	Polyarticular swelling and pain for 5 years, recurrent worsening for over 20 days
RA100	Female	52	Polyarticular pain for 20 years, worsened for 2 months
RA106	Female	48	Recurrent limb polyarticular swelling and pain for over 11 years, worsened for over 2 months
RA110	Male	27	Systemic polyarticular pain for over 10 months
RA112	Female	61	Bilateral finger joint swelling and pain for over 2 years, left ankle joint swelling and pain for 5 months

cated to the high-temperature group. Based on the international standard *Global solar UV index: a practical guide* (WHO), the UV index data were used to allocate patients to high (≥ 7) and low (< 7) UV radiation intensity groups. The original dsDNA measurement data grouped according to temperature and UV intensity are shown in Table 2.

RNA isolation and quantitative PCR

Biochemical analysis was performed with samples from 30 patients with RA and 30 healthy controls. Their baseline characteristics are summarized in Table 3. Whole blood

samples were frozen with Trizol (Invitrogen) at a 1 : 2 ratio and -80°C , then mixed with Trizol at a 1 : 3 ratio before RNA extraction according to the manufacturer's instructions. The RNA was then reverse-transcribed into cDNA using the Evo M-MLV RT Kit and gDNA Clean for quantitative PCR (qPCR; Accurate Biology, Changsha, China). qPCR analysis was performed to detect dsDNA receptor genes using the StepOnePlus Real-Time PCR System (Applied Biosystems) and SYBR Green Premix Pro Taq HS qPCR Kit (Accurate Biology). The primers used are listed

Table 2. dsDNA levels across temperature and UV exposure conditions

	Low temperature (1.2-16.4°C)	High temperature (17-32.3°C)	Low UV (UV index < 7)	High UV (UV index ≥ 7)
dsDNA	1.269432804	1.823676521	1.236234327	1.823676521
	1.443713754	1.610703836	1.037226357	1.610703836
	1.282024585	1.720072519	1.014480369	1.720072519
	1.51395984	1.615311362	1.495987602	1.615311362
	1.358860459	1.299438969	1.044641331	1.299438969
	1.273408541	1.330385908	1.4409521	1.330385908
	1.202008124	2.449900155	1.269452934	2.449900155
	1.209212437	1.458593175	1.252795943	1.458593175
	1.557850788	1.491156417	1.298754445	1.491156417
	1.907916306	1.242742023	1.215380578	1.242742023
	2.277852131	1.056835095	1.286846106	1.056835095
	1.271626999	0.924731227	1.590772701	0.924731227
	0.906301535	0.913917967	1.288466726	0.913917967
	1.272155256	0.893983487	1.304723977	0.893983487
	1.210722938	0.918062842	1.340071639	0.918062842
	1.06550076	0.898702076	1.57053104	0.898702076
	1.007041281	0.94370536	1.272281236	0.94370536
	1.042990188	1.036127348	1.823504947	1.036127348
	1.458738204	0.925512809	1.18751978	0.925512809
	1.129092981	1.10182175	1.572284969	1.10182175
	0.960631823	0.815334791	2.839712274	0.815334791
	1.472077484	0.937868445	1.906775379	0.937868445
	1.126730184	1.019360766	1.232517527	1.019360766
	1.062000681	0.963801977	1.506674155	0.963801977
	0.847500439	0.939635317	1.549706814	0.939635317
	1.069372058	0.982697121	1.903191092	0.982697121
	1.140426919	0.976943352	1.269432804	0.976943352
	1.14549264	0.994711854	1.443713754	0.994711854
	1.332516422	1.236234327	1.282024585	
	0.996184769	1.037226357	1.51395984	
	1.050051552	1.014480369	1.358860459	
	1.092827757	1.495987602	1.273408541	
	0.947647942	1.044641331	1.202008124	
	1.100887993	1.4409521	1.209212437	
	1.476002931	1.269452934	1.557850788	
	1.128887949	1.252795943	1.907916306	
	0.90557567	1.298754445	2.277852131	
	1.04465293	1.215380578	1.271626999	
	1.28399036	1.286846106	0.906301535	
	1.8308355	1.590772701	1.272155256	
	0.972417165	1.288466726	1.210722938	

Table 2. Cont.

Low temperature (1.2-16.4°C)	High temperature (17-32.3°C)	Low UV (UV index < 7)	High UV (UV index ≥ 7)
0.972064528	1.304723977	1.06550076	
0.996253303	1.340071639	1.007041281	
1.006199475	1.57053104	1.042990188	
0.982485804	1.272281236	1.458738204	
0.923728818	1.823504947	1.129092981	
1.008656332	1.18751978	0.960631823	
0.946687486	1.572284969	1.472077484	
0.819021258	2.839712274	1.126730184	
0.774692363	1.906775379	1.062000681	
0.649046212	1.232517527	0.847500439	
0.813708534	1.506674155	1.069372058	
0.699027283	1.549706814	1.140426919	
0.834533093	1.903191092	1.14549264	
0.881554652	1.056032727	1.332516422	
0.99196083		0.996184769	
0.7631915		1.050051552	
0.775593023		1.092827757	
0.788032679		0.947647942	
0.741566159		1.100887993	
0.702747317		1.476002931	
0.873479045		1.128887949	
0.857128694		0.90557567	
0.855239018		1.04465293	
0.834228034		1.28399036	
0.889621785		1.8308355	
0.797688665		0.972417165	
0.684922511		0.972064528	
1.167145582		0.996253303	
1.082059356		1.006199475	
0.923059715		0.982485804	
0.999879671		0.923728818	
0.883020633		1.008656332	
0.877156708		0.946687486	
0.842905287		0.819021258	
0.898078717		0.774692363	
1.407863082		1.056032727	
0.794680437		0.649046212	
1.01180242		0.813708534	
1.107574208		0.699027283	
0.898786286		0.834533093	
0.883694306		0.881554652	

Table 2. Cont.

Low temperature (1.2-16.4°C)	High temperature (17-32.3°C)	Low UV (UV index < 7)	High UV (UV index ≥ 7)
1.349198413		0.99196083	
1.228920165		0.7631915	
2.610056631		0.775593023	
0.950116812		0.788032679	
1.016386789		0.741566159	
0.89062594		0.702747317	
1.204121356		0.873479045	
0.977334914		0.857128694	
1.042092303		0.855239018	
1.114370259		0.834228034	
0.828808988		0.889621785	
0.92588999		0.797688665	
1.271492937		0.684922511	
0.983575926		1.167145582	
1.056269103		1.082059356	
		0.923059715	
		0.999879671	
		0.883020633	
		0.877156708	
		0.842905287	
		0.898078717	
		1.407863082	
		0.794680437	
		1.01180242	
		1.107574208	
		0.898786286	
		0.883694306	
		1.349198413	
		1.228920165	
		2.610056631	
		0.950116812	
		1.016386789	
		0.89062594	
		1.204121356	
		0.977334914	
		1.042092303	
		1.114370259	
		0.828808988	
		0.92588999	
		1.271492937	
		0.983575926	
		1.056269103	

Table 3. Characteristics of healthy controls and rheumatoid arthritis patients analyzed for gene expression analysis

Group	Total (N)	Sex (male/female)	Average age (years)
Healthy control	30	21/9	36
Rheumatoid arthritis	30	6/24	56

in Table 4. Gene expression was calculated using the $2^{-\Delta\Delta CT}$ method with normalization to GAPDH.

Statistical analysis

Differences in gene expression and dsDNA levels were examined using Student's *t* test. Relationships between dsDNA and biochemical parameters – blood pressure and glucose, alanine aminotransferase, aspartate aminotransferase, triglyceride, low-density lipoprotein (LDL), and high-density lipoprotein levels – were assessed using Pearson correlation analysis. For comparisons of non-normally distributed data among more than two groups (e.g., seasonal dsDNA values), the Kruskal-Wallis test with Holm's adjustment for multiple comparisons and post-hoc pairwise Mann-Whitney *U* test were applied. The Mann-Whitney *U* test was also used for the pairwise comparisons of UV intensity among RA groups and of age between patients and controls. Categorical variables were evaluated using the chi-squared test. The independent-samples *t* test and chi-squared distributions were applied as appropriate for other comparative analyses. The analyses were performed using SPSS (version 23.0; IBM Corporation, Armonk, NY, USA). They were conducted with a focus on 95% confidence intervals, and the significance level was set to $p < 0.05$.

Results

Elevation of serum dsDNA levels in patients with RA

Participants' demographic and clinical characteristics and corresponding weather-related data before and after PSM are summarized in Table 5. PSM eliminated significant differences in variables such as age and resulted in a final sample of 150 patients with RA and 408 healthy controls. The mean serum dsDNA concentration was significantly higher in the RA group than in the control group (1.16 ± 0.36 ng/ml vs. 0.92 ± 0.20 ng/ml; $p < 0.001$).

Upregulation of dsDNA receptor gene expression in patients with RA

The expression levels of *CGAS*, *TLR9*, *LRRFIP1*, *POLR3A*, and *KU70* varied notably across the patient and control groups. *LRRFIP1* and *TLR9* expression levels were

Table 4. Primers for quantitative PCR

Gene	Primer sequence (5'→3')
<i>CGAS</i>	F:CACGAAGCCAAGACCTCCG R:GTCGCACTTCAGTCTGAGCA
<i>STING</i>	F:CCAGAGCACACTCTCCGGTA R:CGCATTGGGAGGGAGTAGTA
<i>IFI16</i>	F:AGACTGAAGACTGAACCTGAAGA R:GAACCCATTGCGGCAAACATA
<i>NLRP3</i>	F:GATCTTCGCTGCGATCAACAG R:CGTGCATTATCTGAACCCAC
<i>TLR9</i>	F:CTGCCCTTCTACCCTGTGAG R:GGATGCGGTTGGAGGACAA
<i>ZBP1</i>	F:AACATGCAGTACAATTCCAGA R:AGTCTCGGTTCCATCTTTTGC
<i>LRRFIP1</i>	F:GAATCTAGCGCGCAGTACGAA R:GGCCTCCTTGACTTCAGCAA
<i>POLR3A</i>	F:CCAAGTTGTGAGTAAGAACCCTGT R:CCCATCCTATGGTCGAGCAC
<i>KU70</i>	F:TTGCTTCTGCCTAGCGATACC R:AAACCTGGATCATCAAACCGTT
<i>MRE11</i>	F:ATCGGCCTGTCCAGTTTGA R:TGCCATCTTGATAGTTACCCAT
<i>RAD50</i>	F:TTTGGTTGGACCAATGGGG R:CAGGAGGAAATCTCCAGTACAA
<i>SOX2</i>	F:TACAGCATGTCTACTCGCAG R:GAGGAAGAGGTAACACAGGG
<i>DDX41</i>	F:GGTGGAGGGAGACGGTATCC R:GGCCAGATAGAATGGTGGGG
<i>AIM2</i>	F:TCAAGCTGAAATGAGTCTGC R:CTTGGGTCTCAAACGTGAAGG
<i>PYCARD</i>	F:TGGATGCTCTGTACGGGAAG R:CCAGGCTGGTGTGAAACTGAA
<i>CASP1</i>	F:TTTCCGCAAGGTTTCGATTTTCA R:GGCATCTGCGCTCTACCATC
<i>IL1B</i>	F:TTCGACACATGGGATAACGAGG R:TTTTGTGTGAGTCCCGGAG
<i>RIG1</i>	F:TGTGCTCTACAGGTTGTGGA R:CACTGGGATCTGATTCGCAAAA
<i>MDA5</i>	F:TCGAATGGGTATCCACAGACG R:GTGGCGACTGTCTCTGAA
<i>LGP2</i>	F:GCCCTCGGGTATCATCTTC R:CCCGGATGTCCACAGTCTG
<i>TLR3</i>	F:TTGCCTTGATCTACTTTTGGGG R:TCAACACTGTTATGTTTGTGGGT
<i>TLR7</i>	F:CACATACCAGACATCTCCCA R:CCCAGTGAATAGGTACACAGTT
<i>TLR8</i>	F:ATGTTCTTCAGTCGTCAATGC R:TTGCTGCACTCTGCAATAACT
<i>IFNA1</i>	F:GCCTCGCCCTTTGCTTTACT R:CTGTGGGTCTCAGGGAGATCA
<i>IFNA2</i>	F:GCTTGGGATGAGACCCTCCTA R:CCCACCCCTGTATCACAC
<i>IFNB1</i>	F:GTCAGTGTGCTGGACCATAG R:GTTTCGGAGGTAACCTGTAAGTC
<i>GAPDH</i>	F:GGAGCGAGATCCCTCCAAAAT R:GGCTGTTGTCATACTTCTCATGG

Table 5. Comparison of clinical characteristics before and after propensity score matching (PSM) in patients with rheumatoid arthritis and healthy controls

Characteristics	Before PSM		<i>p</i> -value	After PSM		<i>p</i> -value
	Patients	Healthy controls		Patients	Healthy controls	
No. of patients	152	2994		150	408	
Age (years), median (range)	56 (10-85)	37 (1-86)	< 0.001	56 (10-82)	55 (10-86)	1.000
Sex (%)			< 0.001			0.513
Male	36 (23.7)	1675 (56.9)		36 (24.0)	111 (27.2)	
Female	116 (76.3)	1269 (43.1)		114 (76.0)	297 (72.8)	
Season (%)			< 0.001			< 0.001
Summer	55 (36.2)	1572 (53.4)		55 (36.7)	316 (77.5)	
Autumn	30 (19.7)	40 (1.4)		30 (20.0)	1 (0.2)	
Winter	67 (44.1)	1332 (45.2)		65 (43.3)	91 (22.3)	
Temperature (%)			< 0.001			< 0.001
High	55 (36.2)	1572 (53.4)		55 (36.7)	316 (77.5)	
Low	97 (63.8)	1372 (46.6)		95 (63.3)	92 (22.5)	
UV value (%)			< 0.001			< 0.001
High	28 (18.4)	1572 (53.4)		28 (18.7)	316 (77.5)	
Low	124 (81.6)	1372 (46.6)		121 (81.3)	92 (22.5)	
DsDNA, mean (SD)	1.16 (0.36)	1.00 (0.29)	< 0.001	1.16 (0.36)	0.92 (0.20)	< 0.001

PSM – propensity score matching




Fig. 1. A comparative analysis of dsDNA receptor gene expression was conducted between individuals diagnosed with rheumatoid arthritis (RA) and those classified as healthy controls (HC). HC – healthy controls, RA – rheumatoid arthritis (*n* = 30)




Fig. 2. Significant differences in CASP1 and IL-1β expression between rheumatoid arthritis patients and healthy controls. Real-time PCR analysis was conducted on whole blood levels of AIM2, PYCARD, CASP1 and IL-1β in rheumatoid arthritis patients ($n = 30$) and healthy controls ($n = 30$), relative to GAPDH expression. Data are presented as the mean \pm standard deviation (SD) from three independent experiments ($n = 30$)




Fig. 3. Comparative analysis of the expression levels of type I interferons – specifically IFNα1, IFNα2, and IFNβ1 – between rheumatoid arthritis patients and healthy controls ($n = 30$)

markedly elevated in patients with RA ($p < 0.001$), with *LRRFIP1* showing the most pronounced elevation ($t = 2.95$, $p < 0.001$; Fig. 1).

Upregulation of ALR inflammasome-related inflammatory factors in patients with RA

The expression of absent in melanoma 2 (AIM2) in whole blood samples did not differ significantly between the patient and control groups. The expression of the inflammation-related factors caspase 1 (CASP1) and interleukin 1β (IL-1β) was stronger in the RA group than in the control group (Fig. 2), suggesting that dsDNA activates the AIM2-associated molecular pathway.

Elevation of type I interferon expression in patients with RA

The expression levels of type I interferon (IFN) α1 and IFNβ1 in whole blood samples were significantly higher in the RA group than in the control group. The gene expression level of IFNα2 was similar in the two groups (Fig. 3).

A very weak correlation was observed between LDL and dsDNA values in RA patients

We performed a correlation analysis between serum dsDNA values and various indicators, including glucose, blood pressure, alanine transaminase (ALT), aspartate transaminase (AST), triglycerides (TG), low-density lipoprotein (LDL), and high-density lipoprotein (HDL),




Fig. 4. Pearson correlation analysis of systolic blood pressure, diastolic blood pressure, ALT, AST, glucose, TG, LDL, and HDL levels with dsDNA values in rheumatoid arthritis patients ($n = 30$)




Fig. 5. Correlation between serum dsDNA values and seasonal temperature and UV intensity in RA patients. **A)** Marked fluctuations in dsDNA levels were identified among rheumatoid arthritis patients across the seasons, with the highest levels recorded during the summer, correlating with increased environmental temperatures ($n = 152$). **B)** Elevated temperature conditions were associated with significantly higher dsDNA levels compared to lower temperatures (high temperature: $n = 55$; low temperature: $n = 97$; total $N = 152$). **C)** The study found no significant variation in dsDNA levels when comparing groups subjected to different intensities of UV radiation (high UV: $n = 28$; low UV: $n = 124$; total $N = 152$)

in RA patients. Pearson correlation analysis was used to analyze the correlation between dsDNA and biochemical indicators. We found that serum dsDNA values were very weakly correlated with LDL levels (Fig. 4).

Correlation of serum dsDNA values with seasonal temperature and UV intensity in patients with RA

Among patients with RA, significant inter-group seasonal variations in dsDNA levels were observed among distinct rheumatoid arthritis patient populations across seasonal time points; they were higher during months with higher temperatures than during the low-temperature peri-

od. In contrast, the UV intensity had a minimal impact on the dsDNA level (Fig. 5).

Discussion

Cell-free DNA in the peripheral circulation originates from various sources, including apoptotic cells and neutrophils undergoing NETosis [25]. Under resting conditions, dsDNA is in a state of immune tolerance and does not induce an inflammatory response. Under cellular damage or mitochondrial stress, some endogenous dsDNA undergoes subcellular localization changes, transforming into damage-associated molecular patterns (DAMPs) that can be recognized by the immune system. Pattern recognition receptors (PRRs) can detect DAMPs, such as self-pro-

teins and nucleic acids released during cellular damage. Extracellular DNA is recognized by various DNA sensors through endocytosis, which then triggers an autoimmune response, inducing the expression of inflammatory cytokines. This study showed that serum dsDNA levels and dsDNA receptor expression are elevated in patients with RA relative to healthy controls. Toll-like receptors (TLRs) are PRRs located on cellular and intracellular membranes. They represent an immunological link among infection, tissue damage, and inflammation [26]. TLR9, a DNA sensor, exists in a steady state on endoplasmic reticulum and endosome membranes and can be activated by unmethylated CpG DNA derived from pathogens or by synthetic CpG oligodeoxynucleotides and DNA–protein complexes. Upon sensing DNA, TLR9 drives the interaction between TLR9 adapter proteins and myeloid differentiation factor 88, which further activates the inhibitor of nuclear factor- κ B- α *via* IL-1 receptor-associated kinase 1. This process leads to activation of the transcription factor IFN regulatory factor 7 in the nucleus, thereby promoting the production of IFN- α and IFN- β , which initiate the T helper- α β immune response [27-29]. The observation of elevated type I IFN expression in this study confirms the relationship between serum dsDNA and the inflammatory immune response in patients with RA.

The inflammasome is a multiprotein complex composed primarily of cytosolic sensors from the NLR and ALR families, the apoptosis-associated speck-like protein containing a CARD domain, and the effector protein pro-CASP1 [30]. The effector protein is converted into its enzymatically active form (the cysteine protease CASP1), which induces secretion of IL-1 β . AIM2, a PRR with dsDNA as its explicit ligand, plays a crucial role in the sensing of intracellular environmental disturbances and pathogen invasion due to the widespread distribution of dsDNA in eukaryotic cells. Upon binding to dsDNA, AIM2 assembles a caspase-dependent inflammasome, ultimately cleaving pro-IL-1 β to produce mature IL-1 β and other pro-inflammatory cytokines [31-33]. Additionally, mitochondrial DNA released following mitochondrial damage can activate the nucleotide-binding domain, leucine-rich-containing family, pyrin domain-containing-3 (NLRP3) inflammasome in the cytoplasm, triggering auto-activation of CASP1 and cleavage of the IL-1 β precursor to generate mature IL-1 β [34]. Our serum sample analysis revealed elevated levels of inflammasome-related factors, including CASP1 and IL-1 β , in addition to AIM2, in patients with RA, suggesting a correlation between the peripheral dsDNA level and inflammasome pathways in these patients. These findings point to the potential significance of dsDNA sourced from subcellular damage in this population and underscore the importance of further research on the application of inflammasome pathway inhibitors, such as caspases, in the treatment of RA. Furthermore, Wang *et al.* [35, 36] demonstrated that CASP1

inhibits the cyclic GMP-AMP synthase-stimulator of interferon genes (cGAS-STING) pathway, which aligns with our finding of no significant difference in the expression of the dsDNA receptors cGAS and STING between patients with RA and healthy controls.

LDL is the primary carrier of cholesterol in the peripheral circulation [37], and substantial evidence indicates that it plays significant roles in the initiation and progression of atherosclerotic cardiovascular disease [38, 39]. Findings from a recent study suggested that autoimmune diseases, including RA, can accelerate the onset of atherosclerosis and increase the cardiovascular disease risk [40]. Furthermore, LDL can activate the NLRP3 inflammasome, leading to upregulation of CASP1 and IL-1 β and triggering an inflammatory response [41]. Our study results align with these findings, although the molecular mechanisms of LDL in the pathogenesis of RA require further exploration.

Research teams from Australia, the Netherlands, Sweden, Japan, and other countries have observed that the incidence of RA tends to peak in winter and summer [13, 17, 42, 43]. Partially consistent with these observations, the serum dsDNA levels of patients with RA were higher in summer than in autumn and winter in this study. This finding suggests that seasonal temperature changes influence immune activity by triggering certain physiological responses.

An early study indicated that the risk of RA relapse was increased during the summer, when solar UV radiation is at its highest [44]. However, more recent findings suggest that heat shock proteins released in response to UV radiation mediate a protective immune response through T-cell modulation in patients with RA [45, 46]. Additionally, UV radiation (290-315 nm wavelength) can convert 7-dehydrocholesterol into vitamin D₃, and elevated vitamin D levels have been associated with reduced RA disease activity [47, 48]. Our analysis revealed no significant correlation between the serum dsDNA level and solar UV radiation intensity, potentially attributable to differences in patient behaviors, such as the use of sunscreen, which could mitigate the direct effects of UV radiation. Notably, the influence of meteorological parameters on UV radiation exhibits significant spatial heterogeneity. For instance, the co-occurrence of sub-zero temperatures and high UV indices in high-altitude regions demonstrates that warm weather is not a prerequisite for elevated UV radiation levels.

This study has certain limitations. As most patients experienced significant clinical improvement after RA treatment and very few patients' symptoms persisted across seasons, the collection of relevant samples from the same patients in summer and winter was difficult. Thus, we did not capture continuous seasonal variations in the dsDNA level in the same individuals. However, our study design allowed us to explore seasonal differences between groups with RA onset in different seasons. In addition, we cannot ignore the potential impact of age differences, and strict-

er control of this confounding factor is needed in future research. Finally, the sample was relatively small and consisted of individuals residing in the region surrounding a single hospital. Multicenter research is needed to verify the study findings, and more in-depth research is needed to elucidate the mechanisms underlying the association of the peripheral dsDNA level with the development of RA. In addition, further research is needed to delineate the independent contributions of the temperature, UV radiation, and other seasonal factors to the pathogenesis of RA, as well as the complex interaction among these factors.

Conclusions

The findings of this study contribute to the literature on relationships between seasonal climate factors and diseases, providing additional insights for chronic disease management in clinical practice and offering new perspectives for future research on disease mechanisms.

Funding

This study was supported by Hebei Natural Science Foundation (H2023209084) and S&T Program of Hebei (23372505D).

Disclosures

The study was approved by the Clinical Research Ethics Committee of the First Affiliated Hospital of Anhui Medical University (Quick-PJ2024-06-42).

The authors declare no conflict of interest.

References

- Jiang L, Shang M, Yu S, et al. (2022): A high-fiber diet synergizes with *Prevotella copri* and exacerbates rheumatoid arthritis. *Cell Mol Immunol* 19: 1414-1424.
- Yokota K, Sato K, Miyazaki T, et al. (2021): Characterization and function of tumor necrosis factor and interleukin-6-induced osteoclasts in rheumatoid arthritis. *Arthritis Rheumatol* 73: 1145-1154.
- Almutairi K, Nossent J, Preen D, et al. (2021): The global prevalence of rheumatoid arthritis: a meta-analysis based on a systematic review. *Rheumatol Int* 41: 863-877.
- Chen H, Fu X, Wu X, et al. (2024): Gut microbial metabolite targets HDAC3-FOXK1-interferon axis in fibroblast-like synoviocytes to ameliorate rheumatoid arthritis. *Bone Res* 12: 31.
- Szeto CC, Mok HY, Chow KM, et al. (2008): Climatic influence on the prevalence of noncutaneous disease flare in systemic lupus erythematosus in Hong Kong. *J Rheumatol* 35: 1031-1037.
- Duarte-Garcia A, Fang H, To CH, et al. (2012): Seasonal variation in the activity of systemic lupus erythematosus. *J Rheumatol* 39: 1392-1398.
- van Setten G, Labetoulle M, Baudouin C, Rolando M (2016): Evidence of seasonality and effects of psychrometry in dry eye disease. *Acta Ophthalmol* 94: 499-506.
- Jacoby RK, Jayson MI, Cosh JA (1973): Onset, early stages, and prognosis of rheumatoid arthritis: a clinical study of 100 patients with 11-year follow-up. *Br Med J* 2: 96-100.
- Akerblom A, Helmersson-Karlqvist J, Weitoft T, Larsson A (2017): Seasonal variations of urate in a Swedish adult population. *Clin Rheumatol* 36: 1595-1598.
- Han Y, Sheng Q, Fang Y (2022): Exploring the spatial distribution of rheumatic diseases and its correlation with temperature and humidity among middle-aged and elderly adults in China. *Int J Public Health* 67: 1604782.
- Ferreira ML, Zhang Y, Metcalf B, et al. (2016): The influence of weather on the risk of pain exacerbation in patients with knee osteoarthritis – a case-crossover study. *Osteoarthritis Cartilage* 24: 2042-2047.
- Strusberg I, Mendelberg RC, Serra HA, Strusberg AM (2002): Influence of weather conditions on rheumatic pain. *J Rheumatol* 29: 335-338.
- Abasolo L, Tobías A, Leon L, et al. (2013): Weather conditions may worsen symptoms in rheumatoid arthritis patients: the possible effect of temperature. *Reumatol Clin* 9: 226-228.
- Zeng P, Bengtsson C, Klareskog L, Alfredsson L (2017): Working in cold environment and risk of developing rheumatoid arthritis: results from the Swedish EIRA case-control study. *RMD Open* 3: e000488.
- Huang LJ, Zha JJ, Cao NW, et al. (2022): Temperature might increase the hospital admission risk for rheumatoid arthritis patients in Anqing, China: a time-series study. *Int J Biometeorol* 66: 201-211.
- Wang J, Yu L, Deng J, et al. (2022): Short-term effect of meteorological factors on the risk of rheumatoid arthritis hospital admissions: A distributed lag non-linear analysis in Hefei, China. *Environ Res* 207: 112168.
- de Rooy DP, Andersson MLE, Knevel R, et al. (2012): Does the season at symptom onset influence the long-term severity of radiographic joint destruction in rheumatoid arthritis? *Ann Rheum Dis* 71: 2055-2056.
- Arkema EV, Hart JE, Bertrand KA, et al. (2013): Exposure to ultraviolet-B and risk of developing rheumatoid arthritis among women in the Nurses' Health Study. *Ann Rheum Dis* 72: 506-511.
- McGrath H, Jr., Smith JL, Bak E, Michalski JP (1987): Ultraviolet-A light in the treatment of rheumatoid arthritis. *Clin Exp Rheumatol* 5: 323-328.
- Atamaniuk J, Hsiao YY, Mustak M, et al. (2011): Analysing cell-free plasma DNA and SLE disease activity. *Eur J Clin Invest* 41: 579-583.
- Bartoloni E, Ludovini V, Alunno A, et al. (2011): Increased levels of circulating DNA in patients with systemic autoimmune diseases: A possible marker of disease activity in Sjogren's syndrome. *Lupus* 20: 928-935.
- Mosca M, Giuliano T, Cuomo G, et al. (2009): Cell-free DNA in the plasma of patients with systemic sclerosis. *Clin Rheumatol* 28: 1437-1440.
- Hajizadeh S, DeGroot J, TeKoppele JM, et al. (2003): Extracellular mitochondrial DNA and oxidatively damaged DNA in synovial fluid of patients with rheumatoid arthritis. *Arthritis Res Ther* 5: R234-240.
- Derksen V, Huizinga TWJ, van der Woude D (2017): The role of autoantibodies in the pathophysiology of rheumatoid arthritis. *Semin Immunopathol* 39: 437-446.
- Bronkhorst AJ, Wentzel JF, Aucamp J, et al. (2016): Characterization of the cell-free DNA released by cultured cancer cells. *Biochim Biophys Acta* 1863: 157-165.

26. Hatterer E, Shang L, Simonet P, et al. (2016): A specific anti-citrullinated protein antibody profile identifies a group of rheumatoid arthritis patients with a toll-like receptor 4-mediated disease. *Arthritis Res Ther* 18: 224.
27. Jovasevic V, Wood EM, Cicvaric A, et al. (2024): Formation of memory assemblies through the DNA-sensing TLR9 pathway. *Nature* 628: 145-153.
28. Means TK, Latz E, Hayashi F, et al. (2005): Human lupus autoantibody-DNA complexes activate DCs through cooperation of CD32 and TLR9. *J Clin Invest* 115: 407-417.
29. Honda K, Takaoka A, Taniguchi T (2006): Type I interferon [corrected] gene induction by the interferon regulatory factor family of transcription factors. *Immunity* 25: 349-360.
30. Atianand MK, Rathinam VA, Fitzgerald KA (2013): SnapShot: inflammasomes. *Cell* 153: 272-272.e271.
31. Yang M, Long D, Hu L, et al. (2021): AIM2 deficiency in B cells ameliorates systemic lupus erythematosus by regulating Blimp-1-Bcl-6 axis-mediated B-cell differentiation. *Signal Transduct Target Ther* 6: 341.
32. Liu Z, Han C, Fu YX (2020): Targeting innate sensing in the tumor microenvironment to improve immunotherapy. *Cell Mol Immunol* 17: 13-26.
33. Guo H, Callaway JB, Ting J (2015): Inflammasomes: mechanism of action, role in disease, and therapeutics. *Nat Med* 21: 677-687.
34. Shimada K, Crother TR, Karlin J, et al. (2012): Oxidized mitochondrial DNA activates the NLRP3 inflammasome during apoptosis. *Immunity* 36: 401-414.
35. Wang Y, Ning X, Gao P, et al. (2017): Inflammasome activation triggers caspase-1-mediated cleavage of cGAS to regulate responses to DNA virus infection. *Immunity* 46: 393-404.
36. Banerjee I, Behl B, Mendonca M, et al. (2018): Gasdermin D restrains type I interferon response to cytosolic DNA by disrupting ionic homeostasis. *Immunity* 49: 413-426.e5.
37. Zhou YX, Wei J, Deng G, et al. (2023): Delivery of low-density lipoprotein from endocytic carriers to mitochondria supports steroidogenesis. *Nat Cell Biol* 25: 937-949.
38. Boren J, Chapman MJ, Krauss RM, et al. (2020): Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel. *Eur Heart J* 41: 2313-2330.
39. Emerging Risk Factors Collaboration, Di Angelantonio E, Gao P, Pennells L, et al. (2012): Lipid-related markers and cardiovascular disease prediction. *JAMA* 307: 2499-2506.
40. Mortensen MB, Jensen JM, Sand NPR, et al. (2024): Association of autoimmune diseases with coronary atherosclerosis severity and ischemic events. *J Am Coll Cardiol* 83: 2643-2654.
41. Sharma BR, Kanneganti TD (2021): NLRP3 inflammasome in cancer and metabolic diseases. *Nat Immunol* 22: 550-559.
42. Fleming A, Crown JM, Corbett M (1976): Early rheumatoid disease. I. Onset. *Ann Rheum Dis* 35: 357-360.
43. Mori H, Sawada T, Hishiyama S, et al. (2019): Influence of seasonal changes on disease activity and distribution of affected joints in rheumatoid arthritis. *BMC Musculoskelet Disord* 20: 30.
44. Rozin A, Balbir-Gurman A, Schapira D (2003): Seasonal distribution of relapse onset in rheumatoid arthritis and spondyloarthritis: the possible effect of the solar factor. *Clin Exp Rheumatol* 21: 161-169.
45. Fouani M, Basset CA, Mangano GD, et al. (2022): Heat shock proteins alterations in rheumatoid arthritis. *Int J Mol Sci* 23: 2806.
46. Mantej J, Polasik K, Piotrowska E, Tukaj S (2019): Autoantibodies to heat shock proteins 60, 70, and 90 in patients with rheumatoid arthritis. *Cell Stress Chaperones* 24: 283-287.
47. Holick MF (2007): Vitamin D deficiency. *N Engl J Med* 357: 266-281.
48. Lin J, Liu J, Davies ML, Chen W (2016): Serum vitamin D level and rheumatoid arthritis disease activity: Review and meta-analysis. *PLoS One* 11: e0146351.